Skip to content
  • Clinical Studies
  • Schedule M
  • Stability Studies
  • Pharma GMP
  • Pharma Tips
  • Pharma Books
  • Pharma Validation
  • Pharma Regulatory

SOP Guide for Pharma

The Ultimate Resource for Pharmaceutical SOPs and Best Practices

  • Home
  • SOP Guidelines
    • SOP Development
    • SOP Training
    • SOP Compliance Monitoring
    • SOP Revision Processes
    • Pharmaceutical SOP templates
    • GMP documentation SOP
    • Data integrity SOP pharma
    • Manufacturing SOP pharmaceutical
    • FDA SOP guidance
    • eQMS SOP workflows
  • Job Safety Analysis (JSA)
    • Oral Dosage Forms (Tablets & Capsules)
    • Oral Liquid Dosage Forms (Syrups, Elixirs, Suspensions, Emulsions)
    • Powder and Granule Dosage Forms
    • Topical Dosage Forms (Creams, Ointments, Gels, Lotions, Pastes)
    • Transdermal Dosage Forms (Patches)
  • Standard Test Procedures (STP)
  • GMP Audit Findings
    • Non-Compliance
      • SOP Absence
      • Revision Control
      • Non-Adherence
      • Poor Writing
      • Training Failure
      • Data Integrity Gaps
      • Mismatch Between SOPs and Practice
      • Critical Operations
      • Regulatory Change
      • Emergency Changes
      • Third-Party SOPs
      • Inspection Readiness
      • Deviation Handling
      • CAPA Integration
      • Validation Alignment
      • System Integration
      • Uncontrolled Distribution
      • SOP Implementation Gaps
      • SOP Alignment with Validation
      • Change Control Linkage
  • Toggle search form

Biosimilars: SOP for Environmental Monitoring During Purification – V 2.0

Posted on By


Biosimilars: SOP for Environmental Monitoring During Purification – V 2.0


Standard Operating Procedure for Environmental Monitoring During Purification in Biosimilar Manufacturing

Department Biosimilars
SOP No. SOP/BS/196/2025
Supersedes SOP/BS/196/2022
Page No. Page 1 of 10
Issue Date 04/05/2025
Effective Date 06/05/2025
Review Date 04/05/2026

1. Purpose

To establish a comprehensive and GMP-compliant procedure for environmental monitoring (EM) during the purification processes in biosimilar manufacturing to detect microbial and particulate contamination in controlled areas.

2. Scope

This SOP applies to viable and non-viable monitoring activities carried out in Grade B and C areas where biosimilar purification activities are conducted, including chromatography, filtration, and hold steps.

3. Responsibilities

  • Microbiology/EM Analyst: Perform sampling, incubation, and data recording for all EM parameters.
  • Production: Support coordination during operation-based sampling and report any abnormal conditions.
  • QA: Review EM data, approve trend reports, and take decisions in case of alert/action level excursions.

4. Accountability

The Head of Microbiology is accountable for implementation and evaluation of the EM program to ensure environmental control during downstream biosimilar processing.

5. Procedure

5.1 EM Sampling Plan

  1. Define EM plan based on risk assessment of purification activities and classified areas.
  2. Include sampling points for:
    • Airborne viable count (settle plates and active air sampling)
    • Non-viable particulate monitoring (0.5 µm and 5.0 µm)
    • Surface monitoring (contact plates/swabs)
    • Personnel monitoring (gloves, gown)
  3. Frequency: Daily (critical steps), weekly (routine), and per batch (process monitoring).

5.2 Viable Monitoring

  1. Expose settle plates for 4 hours at critical sites such as chromatography skids, filtration units.
  2. Use portable active air sampler calibrated for 1,000 L of air; position near operator workstation and process area.
  3. Perform contact plate sampling on cleaned surfaces post-operation (Annexure-1).
  4. Incubation conditions:
    • 30–35°C for 3–5 days
    • 20–25°C for 5–7 days

5.3 Non-Viable Monitoring

  1. Use calibrated particle counter during operations to monitor 0.5 µm and 5.0 µm particles.
  2. Monitor during filtration, bulk transfer, and other critical open operations.
  3. Log particle count results in Annexure-2. Ensure compliance with ISO Class 7/8 limits as applicable.

5.4 Personnel Monitoring

  1. Collect fingertip and gown surface samples from operators at end of operation.
  2. Record results and compare with limits:
    • Fingertip: ≤ 10 cfu/glove
    • Gown surface: ≤ 5 cfu/plate
  3. Deviations must be investigated (Annexure-3).

5.5 Alert and Action Limits

  1. Establish limits based on area classification and historical trending.
  2. If alert limit is breached: monitor additional samples and initiate alert notification.
  3. If action limit is breached: quarantine product, initiate deviation/CAPA, and investigate root cause.

5.6 Trend Analysis and Reporting

  1. Monthly EM trend reports to be prepared and reviewed by QA and Microbiology.
  2. Identify upward trends, repeat observations, and seasonal variation.
  3. Submit to QA for periodic review and regulatory compliance.

6. Abbreviations

  • EM: Environmental Monitoring
  • cfu: Colony Forming Unit
  • QA: Quality Assurance
  • CAPA: Corrective and Preventive Action

7. Documents

  1. Surface Monitoring Log – Annexure-1
  2. Non-Viable Particulate Log – Annexure-2
  3. EM Deviation Report – Annexure-3

8. References

  • EU GMP Annex 1 – Manufacture of Sterile Medicinal Products
  • ISO 14644 – Cleanroom Classification Standards
  • WHO TRS 961 – GMP for Biologics

9. SOP Version

Version: 2.0

10. Approval Section

Prepared By Checked By Approved By
Signature
Date
Name
Designation
Department

11. Annexures

Annexure-1: Surface Monitoring Log

Date Location Plate ID cfu Count Operator
04/05/2025 Chromatography Skid SP-145 2 Ajay Verma

Annexure-2: Non-Viable Particulate Log

Date Location 0.5 µm Count 5.0 µm Count Operator
04/05/2025 Buffer Transfer Point 2,120 80 Sunita Reddy

Annexure-3: EM Deviation Report

Date Location Parameter Observation CAPA QA Reviewed
03/05/2025 Grade C Filtration Zone Settle Plate 14 cfu Repeat cleaning, enhanced monitoring Dr. Neha Rao

Revision History:

Revision Date Revision No. Details Reason Approved By
04/05/2025 2.0 Added trend analysis section and alert/action handling protocols Regulatory Enhancement
See also  Biosimilars: SOP for Small-Scale Expression Screening - V 2.0
Biosimilars V 2.0 Tags:biosimilar manufacturing SOP, biosimilar process validation SOP, biosimilar quality control procedure, cell line development SOP biosimilars, chromatography SOP biosimilars, cleaning validation SOP for biosimilar equipment, cleanroom SOP for biologics manufacturing, deviation handling SOP in bioprocess, downstream processing SOP, environmental monitoring SOP biosimilars, GMP SOP for biosimilars, host cell protein removal SOP, inline UV monitoring SOP biosimilars, media preparation SOP for biosimilars, protein purification SOP, purification skid calibration SOP, SOP for bioreactor inoculation biosimilars, SOP for biosimilar cell banking, SOP for cell culture in biosimilar production, SOP for chromatography column packing, SOP for ELISA-based clone screening, SOP for endotoxin testing in biologics, SOP for filter sterilization in downstream processing, SOP for glycosylation analysis in biosimilars, SOP for master cell bank, SOP for protein A chromatography steps, SOP for resin qualification in biosimilar purification, SOP for viral clearance in biosimilar production, SOP for working cell bank, upstream processing SOP biosimilars

Post navigation

Previous Post: Packaging: SOP for Visual Inspection of Packed Injectable Products – V 2.0
Next Post: Elixir Department: SOP for Use of Validated Cleaning Detergents – V 2.0

Standard Operating Procedures V 1.0

  • Aerosols
  • Analytical Method Development
  • Bioequivalence Bioavailability Study
  • Capsule Formulation
  • Clinical Studies
  • Creams
  • Data Integrity
  • Dental Dosage Forms
  • Drug Discovery
  • Environment, Health and Safety
  • Formulation Development
  • Gels
  • Good Distribution Practice
  • Good Warehousing Practices
  • In-Process Control
  • Injectables
  • Liquid Orals
  • Liposome and Emulsion Formulations
  • Lotions
  • Lyophilized Products
  • Maintenance Dept.
  • Medical Devices
  • Metered-Dose Inhaler
  • Microbiology Testing
  • Nanoparticle Formulation
  • Nasal Spray Formulations
  • Nebulizers
  • Ocular (Eye) Dosage Forms
  • Ointments
  • Otic (Ear) Dosage Forms
  • Pharmacovigilance
  • Powder & Granules
  • Purchase Departments
  • Quality Assurance
  • Quality Control
  • Raw Material Stores
  • Regulatory Affairs
  • Tablet Manufacturing
  • Rectal Dosage Forms
  • Transdermal Patches
  • Vaginal Dosage Forms
  • Validations and Qualifications

Read SOPs in your Language:

 - 
Bengali
 - 
bn
English
 - 
en
Gujarati
 - 
gu
Hindi
 - 
hi
Malayalam
 - 
ml
Marathi
 - 
mr
Punjabi
 - 
pa
Tamil
 - 
ta
Telugu
 - 
te

NEW! Revised SOPs – V 2.0

  • Aerosols V 2.0
  • Analytical Method Development V 2.0
  • API Manufacturing V 2.0
  • BA-BE Studies V 2.0
  • Biosimilars V 2.0
  • Capsules V 2.0
  • Creams V 2.0
  • Elixers V 2.0
  • Gels V 2.0
  • Injectables V 2.0
  • Ointments V 2.0
  • Raw Material Warehouse V 2.0
  • Tablet Manufacturing V2.0

New Publication: A must for All.

Copyright © 2025 SOP Guide for Pharma.

Powered by PressBook WordPress theme

Go to mobile version